Bio-Implants Market (Cardiovascular, Orthopaedics, Neurostimulation, Xenografts, Allografts and Others) Competitive Analysis and Global Forecast to 2017
"Bio-Implants Market by Products (Cardiovascular, Spine, Orthopedics &
Trauma, Dental, Drug & Other Implants), Mode of Administration (Surgical &
Injectable/Non-Surgical), By Origin (Allograft, Autograft, Xenograft,
Synthetic), and by Material (Ceramics, Biomaterial, Alloys, & Polymers) -
Competitive Landscape, Opportunities and Global Forecasts (2012-2017)"
Bio-implants can be defined as prostheses used to regularize physiological
functions. They are made up of biosynthetic materials like collagen, and
tissue-engineered products like artificial skin or tissues. Most bioengineered
products like cardiac pacemakers and orthopedic artificial implants are also
covered under bio-implants, since they are implanted entirely in the patient's
body.
Bio-implants are mostly classified at a broader level as:
Biological implants (cell therapy, bioartificial organs and tissue
engineering)
Biologised implants (technical implants, biohybrid systems, in vivo cell
lining)
According to the Centers for Disease Control and Prevention (CDC), there were
40 million people aged 65 and above in the United States in 2010, accounting
for 13% of the total population. The older population in 2030 is projected to
be twice as large as in 2000, growing from 35 million to 72 million and
representing nearly 20% of the total U.S. population. This growth in aging
population is expected to push the growth of the dental, reconstructive joint
replacement, ophthalmic, and neuromodulation implants markets.
This report describes the growth opportunities in the global bio-implants
market. It focuses on the increase in demand for technologically advanced
products that may help in faster recovery and better efficacy of physiological
body functions.
The global bio-implants market is estimated to be $94.1 billion in 2012 and is
poised to grow at a CAGR of 7.3% from 2012 to 2017. Rise in the aging
population and increase in incidences of chronic diseases like osteoarthritis,
old age-related trauma, cardiovascular diseases, neuropathic disorders
(Alzheimer's disease and Parkinson's), and congenital disorders and
deformities is expected to trigger the growth of this market.
The major players in this market are Stryker Corporation (U.S.), Synthes
(U.S.), Boston Scientific Corporation (U.S.), Biomet, Inc. (U.S.), Smith &
Nephew (U.K.), Medtronic (U.S.), St. Jude Medical, Inc. (U.S.), Tornier N.V.
(The Netherlands), and others.
Scope of the Report
The global bio-implants market is segmented by types, which include major
segments such as orthopedic, cardiovascular, dental, ophthalmic,
neurostimulation, and others, and by origin (allograft, autograft, xenograft,
and synthetic). Each market is comprehensively analyzed at a granular level by
geography (North America, Europe, Asia, and Rest of the World) to provide
in-depth information on the global scenario.
Global bio-implants market segmentation
By types
Cardiovascular Implants
Pacing Devices
Cardiac Resynchronization Therapy Devices (CRTs)
Implantable Cardioverter Defibrillators (ICDs)
Implantable Cardiac Pacemakers (ICPs)
Pacing Accessories
1. Pacing Leads
2. Pacing Batteries
Stents & Related Implants
Coronary Stents
1. Drug-Eluting Stents
2. Bare-Metal Coronary Stents
3. Bioabsorbable stents
Peripheral Stents
1. Endovascular Stent-Grafts
2. Renal & Related Stents
3. Femoral & Related Stents
4. Carotid Stents
Stent-related Implants
1. Synthetic Grafts
2. Vascular Grafts
3. Peripheral Grafts
4. Vena Cava Filters
Structural Cardiac Implants
Heart Valves & Accessories
Tissue Heart Valves
Mechanical Heart Valves
Heart Valve Repair Devices
Ventricular-Assist Devices
Implantable Heart Monitors
Insertable Loop Recorders (ILRs)
Implantable Hemodynamic Monitors (IHMs)
Spinal Implants
Thoracolumbar Implants
Intervertebral Spacers
Machined Allograft Spacers
Cervical Implants
Motion Preservation Implants
Implantable Spinal Stimulators
Orthopedics & Trauma
Reconstructive Joint Replacements
Knee Replacement Implants
Hip Replacement Implants
Extremities
1. Shoulder Implants
2. Elbow Replacements
3. Ankle Implants
4. Other Joint replacements fusion products
Orthobiologics
Hyaluronic Acid
Bone Substitutes
Bone Growth Factors
Bone Cement
Tissue Implants
Trauma Implants
Internal Trauma Fixation Devices
Craniomaxillofacial Fixation Devices
Implantable Trauma Stimulators
Sports Medicine
Dental
Plate form dental implants
Root form dental implants
Ophthalmic Implants
Intraocular Lens
Glaucoma & Other Lenses
Neurostimulators Implants
Cortical Stimulators
Deep Brain Stimulators
Sacral Nerve Stimulators
Spinal Cord Stimulators
Vagus Nerve Stimulators
Others
Gynecological Devices
Drug Implants
Otolaryngeal Implants
Cosmetic Implants
Gastroenterological Implants
Urological Implants
Skin & Wound Care
By origin
Allograft
Autograft
Xenograft
Synthetic
By materials
Ceramics (zirconium)
Biomaterial metal (titanium, gold, silver, platinum)
Alloys
Polymers (natural polymers & synthetic polymers)
By geography
North America
Europe
Asia
RoW (Rest of the World)
Summary
The use of bio-implants to restore biological structures of the body dates
back to the beginning of the 20th century. The early applications of
bio-implants included replacement, repair and restoration of hard tissues such
as bones, as well as soft tissues including organs, and skin. Over the
century, these have evolved and are now used for not just structural revamps,
but for various purposes such as for delivering drugs internally to the body
and for hormone replacement. They have vast applications and also include
electronic battery-operated devices, which help correct the pace of heart
beats as well as send interference signals to the nervous system. Their
superiority to drugs in treating certain illnesses has been acknowledged
globally. Considering the continued quest for better, safer and more effective
implants, dealing with diseases is expected to become easier, more cost
effective and faster.
The most preferred bio-implants are those of biological origin as they are
easily compatible with the body environment. However, synthetic bio-implants
are also being increasingly used. Advances in tissue engineering have enabled
researchers to prepare artificial prostheses having improved compatibility
with the human body The various artificial materials used for preparing
bio-implants include metals, ceramics, and special plastic or polymers
The overall bio-implants market is being driven by aging populations, rising
incidence of diseases and conditions such as obesity, stress, changing
lifestyles, increasing awareness, patient acceptance, product innovation, and
increased clinical evidence to prove safety and efficacy of implants.
The global bio-implants market was valued at $94.1 billion for 2012; North
America has been, and is expected to be, the largest region for this market,
Europe being the second, followed by Asia. The Asian region is set to record
the highest CAGR in the global bio-implants market.
The dominant players in the global bio-implants market include Medtronic, St.
Jude Medical, Stryker, Boston Scientific, DePuy Synthes, C R Bard, Gore (WL) &
Associates Incorporated, Abbott Laboratories, Braun (B.) Melsungen AG, Edwards
Lifesciences Corporation Sorin SpA, Zimmer Holdings, Nobel Biocare, Straumann,
Dentsply/Astratech, Biomet/3i, Novartis(Alcon), Bausch & Lomb, Cyberonics,
Johnson & Johnson, Integra Life Sciences, and Smith & Nephew.
Table of Contents
Table of Contents
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 EVOLUTION
3.3 MARKET SEGMENTATION
3.4 MARKET DYNAMICS
3.4.1 DRIVERS
3.4.1.1 Rise in aging population triggers market growth
3.4.1.2 Innovation in implants technologies is driving the growth
3.4.1.3 Changing lifestyles to propel the demand for advanced
bio-implants
3.4.1.4 Increased awareness about cosmetic implants
3.4.1.5 Non-surgical bio-implants to propel growth in this market
3.4.1.6 Emerging preference for MIS surgeries
3.4.2 RESTRAINTS
3.4.2.1 High cost of implants to confine the growth of the
bio-implants market
3.4.2.2 Hostile reimbursement issues to curb the growth of the
bio-implants market
3.5 MARKET SHARE ANALYSIS
3.5.1 CARDIAC
3.5.2 ORTHOPAEDICS
3.5.3 DENTAL
3.5.4 SPINAL
3.5.5 NEUROSTIMULATION
3.5.6 OPHTHALMIC
3.6 BIO-IMPLANTS, BY NON-SURGICAL MODE OF ADMINISTRATION
TABLE 100 AAP IMPLANTATE AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 101 AAP IMPLANTATE AG: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 102 AAP IMPLANTATE AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 103 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 104 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 105 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 106 BIOMET, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011
($MILLION)
TABLE 107 BIOMET, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 108 BIOMET, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 109 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D
EXPENDITURE, 2009 - 2011 ($MILLION)
TABLE 110 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009
- 2011 ($MILLION)
TABLE 111 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE OF CORONARY STENT
SYSTEM, 2009 - 2011 ($MILLION)
TABLE 112 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE OF CRM SEGMENT,
2009 - 2011 ($MILLION)
TABLE 113 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009
- 2011 ($MILLION)
TABLE 114 C.R. BARD, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011
($MILLION)
TABLE 115 C.R. BARD, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 116 C.R. BARD, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 117 EDWARDS LIFESCIENCES CORPORATION: TOTAL REVENUE AND R&D
EXPENDITURE, 2009 - 2011 ($MILLION)
TABLE 118 EDWARDS LIFESCIENCES CORPORATION: TOTAL REVENUE, BY PRODUCTS,
2009 - 2011 ($MILLION)
TABLE 119 EDWARDS LIFESCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION)
TABLE 120 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,
2009 - 2011 ($MILLION)
TABLE 121 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 -
2011 ($MILLION)
TABLE 122 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 123 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 124 JOHNSON & JOHNSON: MEDICAL DEVICES AND DIAGNOSTICS REVENUE, BY
SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 125 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 126 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: TOTAL REVENUE AND R&D
EXPENDITURE, 2009 - 2011 ($MILLION)
TABLE 127 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: TOTAL REVENUE, BY
SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 128 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: TOTAL REVENUE, BY
GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 129 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 - 2012
($MILLION)
TABLE 130 MEDTRONIC, INC.: TOTAL REVENUE, BY SEGMENTS, 2010 - 2012
($MILLION)
TABLE 131 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012
($MILLION)
TABLE 132 MIMEDX GROUP, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 133 ORTHOFIX INTERNATIONAL N V: TOTAL REVENUE AND R&D EXPENDITURE,
2009 - 2011 ($MILLION)
TABLE 134 ORTHOFIX INTERNATIONAL N.V.: TOTAL REVENUE, BY SEGMENTS, 2009 -
2011 ($MILLION)
TABLE 135 ORTHOFIX INTERNATIONAL N.V.: TOTAL REVENUE OF SPINE SEGMENT,
2009 - 2011 ($MILLION)
TABLE 136 SMITH & NEPHEW, PLC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 137 SMITH & NEPHEW PLC: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 138 SMITH & NEPHEW, PLC: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 139 SORIN S.P.A.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011
($MILLION)
TABLE 140 SORIN S.P.A.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 141 SORIN S.P.A.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 142 ST. JUDE MEDICAL, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009
- 2010 ($MILLION)
TABLE 143 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 144 ST. JUDE MEDICAL, INC.: TOTAL REVENUE OF CARDIAC RHYTHM
MANAGEMENT SEGMENT ($MILLION)
TABLE 145 ST. JUDE MEDICAL, INC.: TOTAL REVENUE OF CARDIOVASCULAR SEGMENT,
2009 - 2011 ($MILLION)
TABLE 146 ST. JUDE MEDICAL, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 147 STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 148 STRYKER CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009-2011
($MILLION)
TABLE 149 STRYKER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 150 THORATEC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 151 THORATEC CORPORATION: TOTAL REVENUE, BY PRODUCT LINE, 2009 -
2011 ($MILLION)
TABLE 152 THORATEC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
TABLE 153 TORNIER N.V.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011
($MILLION)
TABLE 154 TORNIER N.V.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 155 TORNIER N.V.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 156 WRIGHT MEDICAL GROUP INCORPORATED: TOTAL REVENUE AND R&D
EXPENDITURE, 2009 - 2011 ($MILLION)
TABLE 157 WRIGHT MEDICAL GROUP INCORPORATED: TOTAL REVENUE, BY SEGMENTS,
2009 - 2011 ($MILLION)
TABLE 158 WRIGHT MEDICAL GROUP INCORPORATED: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION)
TABLE 159 ZIMMER HOLDINGS, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 -
2011 ($MILLION)
TABLE 160 ZIMMER HOLDINGS, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011
($MILLION)
TABLE 161 ZIMMER HOLDINGS, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011
($MILLION)
LIST OF FIGURES
FIGURE 1 BIO-IMPLANTS MARKET SEGMENTATION
FIGURE 2 MARKET DYNAMICS
FIGURE 3 GLOBAL CARDIAC MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 4 GLOBAL ORTHOPAEDICS MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 5 GLOBAL DENTAL MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 6 GLOBAL SPINAL MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 7 GLOBAL NEUROSTIMULATION MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 8 GLOBAL OPHTHALMIC MARKET SHARE ANALYSIS, BY PLAYERS, 2011
FIGURE 9 KEY GROWTH STRATEGIES, JANUARY 2009 - JULY 2012
FIGURE 10 NEW PRODUCT LAUNCH STRATEGY, BY COMPANY, JANUARY 2009 - JULY 2012
FIGURE 11 KEY GROWTH STRATEGIES, BY COMPANY, JANUARY 2009 - JULY 2012
Bio-Implants Market (Cardiovascular, Orthopaedics, Neurostimulation, Xenografts, Allografts and Others) Competitive Analysis and Global Forecast to 2017 published by Markets and Markets in September 1, 2012. This report consists of 607 Pages and the price starts from US $ 4650.
